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ardiac Medical Therapy in Patients After
ndergoing Coronary Artery Bypass Graft Surgery
Review of Randomized Controlled Trials
aren Okrainec, BSC, MSC,* Robert Platt, PHD,† Louise Pilote, MD, MPH, PHD,‡
ark J. Eisenberg, MD, MPH, FACC§
ontreal, Quebec, Canada
The purpose of this paper is to review the randomized controlled trial (RCT) data
investigating cardiac medical therapy for patients after coronary artery bypass grafting
(CABG). We identified RCTs with 100 enrolled patients that examined the impact of
cardiac medical therapy on outcomes 1 year after CABG. The MEDLINE database was
searched for trials conducted between 1966 and 2004 on the following medications: aspirin,
antilipid agents, beta-blockers, calcium channel blockers (CCBs), nitrates, and angiotensin-
converting enzyme (ACE) inhibitors. Both aspirin and antilipid agents were found to reduce
the progression of atherosclerosis and the occurrence of graft occlusion. Cardiovascular events
were decreased with antilipid agents. In small trials, beta-blockers and CCBs failed to
decrease the incidence of cardiovascular events. No RCTs examined nitrates, and one small
RCT documented a reduction in cardiovascular events among patients treated with ACE
inhibitors. We conclude that few RCTs have examined the efficacy of cardiac medical therapy
in post-CABG patients. Based on current RCT evidence, aspirin and antilipid agents should
be used routinely after CABG. However, current data do not support the use of beta-blockers,
CCBs, and nitrates, and more evidence is needed regarding the use of ACE
inhibitors. (J Am Coll Cardiol 2005;45:177–84) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.065Cardiology Foundation
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mhe efficacy of coronary artery bypass grafting (CABG) is
ell established in patients with coronary artery disease
CAD) (1–6). However, patients undergoing CABG are
till at risk for unstable angina, myocardial infarction (MI),
nd death through the progression of native coronary artery
therosclerosis as well as the occlusion of bypass grafts
7–10). In the post-CABG patient, secondary prevention
ncludes the use of appropriate medical therapy to prevent
he occurrence of clinical events. Numerous randomized
linical trials (RCTs) and observational studies have been
ublished on the efficacy of cardiac medical therapy for
atients with known CAD who have specific cardiovascular
omorbidities (11–26). For example, patients with CAD
enefit from antiplatelet and antilipid agents (11–15),
hereas patients with depressed left ventricular ejection
raction (LVEF) and diabetes benefit from angiotensin-
onverting enzyme (ACE) inhibitors (21–23). Although the
merican College of Cardiology/American Heart Associa-
From the *Department of Epidemiology and Biostatistics, McGill University,
ontreal, Quebec, Canada; †Department of Clinical Epidemiology, Montreal
hildren’s Hospital, Montreal, Quebec, Canada; ‡Divisions of Internal Medicine and
linical Epidemiology, McGill University Health Center, Montreal, Quebec,
anada; and §Divisions of Cardiology and Clinical Epidemiology, Jewish General
ospital, McGill University, Montreal, Quebec, Canada. Dr. Eisenberg is a Senior
hysician-Scientist of the Fonds de la Recherche en Santé du Québec. Dr. Pilote is
Physician-Scientist of the Canadian Institutes of Health Research. Karen Okrainec
as supported with funding for her Master’s thesis from the Fonds de la Recherche
n Santé du Québec (FCAR-Santé).i
Manuscript received December 19, 2003; revised manuscript received August 4,
004, accepted September 28, 2004.ion guidelines for CABG recommend the use of both
spirin and antilipid agents after CABG, there is no
iscussion regarding the use of medications such as beta-
lockers, calcium channel blockers (CCBs), nitrates, or
CE inhibitors (25). Thus, there is a lack of consensus on
hat is the appropriate medical therapy for patients who
ave undergone CABG. The purpose of this paper is to
eview the RCT literature on cardiac medical therapy for
atients after CABG.
ETHODS
tudy selection. We identified RCTs that examined the
ffects of cardiac medications after CABG conducted be-
ween the years 1966 and 2004 and published in the English
anguage. The MEDLINE database was searched for RCTs
nvolving the use of the following medications: aspirin,
ntilipid agents (specifically using the terms antilipemic and
nticholesteremic agents including hydroxymethylglutaryl-
oA reductase inhibitors), beta-blockers, CCBs, nitrates,
nd ACE inhibitors. We also used “coronary artery bypass
raft surgery” as a key term, and limited our search to RCTs
nd their follow-up studies. Lastly, we reviewed references
rom these articles for pertinent studies not previously found
hrough the MEDLINE database search.
nclusion and exclusion criteria. Placebo-controlled
CTs that tested the efficacy of the aforementioned cardiac
edications were included. We included trials that exam-ned the impact of medical therapy on cardiovascular out-
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RCTs of Post-CABG Medical Therapy January 18, 2005:177–84omes including unstable and stable angina, MI, cardiovas-
ular death, and overall mortality as well as native coronary
rtery and bypass graft occlusion and the need for further
evascularization by percutaneous coronary intervention
PCI) or repeat CABG. Trials that investigated the role of
eta-blockers or CCBs on atrial fibrillation were not in-
luded, nor were trials that investigated the role of nitrates
r CCBs on vasospasm. Only trials that examined native
oronary artery and bypass graft occlusion by angiography
ere included. Trials with mixed outcomes of graft occlu-
ion and cardiovascular events were also included.
We excluded all trials that randomized 100 patients.
his was done in order to exclude studies conducted with
imited power and studies with limited enrollment where
he quality of the methodology used may have been ques-
ionable and was difficult to assess. We also excluded all
rials that examined outcomes 1 year after CABG. This
as done for two reasons: first, we were interested in the
ffects of medications on long-term secondary prevention;
nd, second, we wanted to exclude all trials that studied
vents that could be a result of the operation itself. There-
ore, we did not review the effect of cardiac medical therapy
n early graft patency, although some authors reported both
arly and late graft patency (1 year). Moreover, we
xcluded all trials that tested the use of cardiac medications
efore CABG or perioperatively unless the use of the
edication continued after hospital discharge. Trials that
pecifically examined the use of cardiac medications in
nother subset of cardiac patients, such as post-MI or
ost-PCI, despite a large majority of these patients having
rior CABG, were also excluded. This was done because the
tudy population did not include all patients with previous
ABG, and the time since CABG was frequently not
eported. Observational studies or in vitro studies were,
ikewise, not included in this review.
EDICAL THERAPY AMONG CAD PATIENTS
ND PATIENTS WITH OTHER COMORBIDITIES
he focus of this paper is to specifically review RCTs of
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CABG  coronary artery bypass grafting
CAD  coronary artery disease
CCB  calcium channel blocker
CHF  congestive heart failure
CLAS  Cholesterol Lowering Atherosclerotic
Study
LOCAT  Lopid Coronary Angiography trial
LVEF  left ventricular ejection fraction
MI  myocardial infarction
PCI  percutaneous coronary intervention
QUO VADIS  Quinapril on Clinical Outcome After
Coronary Artery Bypass Grafting study
RCT  randomized clinical trialardiac medical therapy in the post-CABG patient. How- fver, our review would not be complete without the mention
f the substantial evidence that exists on the efficacy of these
edications among patients with CAD and patients who
ave other comorbid conditions. The latter often make up a
arge proportion of patients who undergo CABG, and many
f the studies in this section have patient populations that
ncluded patients who underwent CABG.
Numerous RCTs have shown aspirin to be beneficial in
educing the risk of adverse cardiovascular events such as
I and death in a wide range of patients. The use of aspirin
as been found to significantly decrease the incidence of
oth nonfatal MI and nonfatal stroke among patients with
AD and among patients with various comorbidities in-
luding: atrial fibrillation, prior MI, peripheral vascular
isease, post-PCI, and unstable angina (24). Antilipid
gents have been found to be efficacious for plaque stabili-
ation in native arteries, and in preventing MI and cardiac
eath among patients with CAD (12–15).
Beta-blockers have both anti-ischemic and antihyperten-
ive properties. These agents have been found to be of
enefit in the prevention of recurrent MI and death among
atients with a history of MI as well as post-MI subgroups
uch as the diabetic elderly (16,17). An improvement in
urvival has also been found with the use of beta-blockers in
atients with congestive heart failure (CHF) (18,19). Both
CBs and nitrates have been found to be beneficial in
reating angina among patients with unstable and stable
ngina who have contraindications to beta-blockers (20).
itrates have been found to be especially useful among
atients with angina who also have left ventricular dysfunc-
ion (20). However, because beta-blockers have also been
ound to reduce mortality in MI patients, beta-blockers are
ften used as the first-line agents for the treatment of
ngina. Lastly, both beta-blockers and CCBs are also used
n treating hypertension. The ACE inhibitors have been
hown to be of benefit in post-MI patients and patients with
HF, diabetes, depressed left ventricular function, and
ypertension (21–23). Risk reduction in the composite end
oint of MI, stroke, or death has also been demonstrated
mong patients receiving ACE inhibitors with diabetes,
eripheral vascular disease, or a history of CAD without
eart failure or left ventricular dysfunction (22).
CTs OF MEDICAL
HERAPY IN THE POST-CABG PATIENT
total of 14 RCTs were found that examined the efficacy
f aspirin, antilipid agents, beta-blockers, CCBs, nitrates,
nd ACE inhibitors specifically among patients after
ABG.
SPIRIN
e found 8 RCTs involving more than 2,500 patients that
tudied the use of aspirin after CABG (Table 1) (26–33).
he number of patients randomized in these trials rangedrom 147 to 772 patients, and dosages used in these studies
Table 1. Randomized Controlled Trials of Aspirin Use in Post-CABG Patients
Author, Year (Ref.)
Number
Randomized Medication and Dose
Treatment Onset
(No. Days Pre- or
Post-Op)
Follow-Up
Time
(Months)
% With
Follow-Up
Angiography
Events
p
Value
Aspirin
(%)
Control
(%)
Angiographic end point: number of patients with one
or more grafts occluded at follow-up angiography
Goldman et al., 1989 (26) 772 Aspirin 325 mg qd-tid 
75 mg dipyridamole tid*
1# 12‡ 65§ 105/299 (35) 47/107 (44) 0.10
Chesebro et al., 1984 (27) 407 Aspirin 325 mg qd 
dipyridamole 75 mg tid
0# 12‡ 84 12/171 (7) 30/172 (17) 0.003
Goldman et al., 1994 (28)† 334 Aspirin 325 mg qd 365 36 86 (31.4)† (37.8)† 0.26
Brooks et al., 1985 (29) 320 Aspirin 320 mg 
dipyridamole 75 mg tid
2–3# 12 83 33/133 (25) 37/133 (28) 0.05¶
Gavaghan et al., 1991 (30) 237 Aspirin 324 mg qd 0 12‡ 92 14/119 (12) 30/100 (30) 0.001
McEnany et al., 1982 (31) 216 Aspirin 600 mg bid 3–4 21.5 50 15/40** (37) 16/37** (43) 0.05¶
Sharma et al., 1983 (32) 176 Aspirin 325 mg tid 3–5 12 81 22/50** (44) 20/44** (46) 0.05¶
Brown et al., 1985 (33) 147 Aspirin 325 mg tid 2–3 12 86 10/38** (26) 18/44** (41) 0.05¶
Clinical end point: mean number of patients with MI
at follow-up
Goldman et al., 1989 (26) 772 1 12‡ 65 4.0 0.9 0.12
Goldman et al., 1994 (28) 334 365 36 86 1.9  13.6 1.7  13.1 0.93
*In this study, patients were randomized to either of four treatment arms (aspirin 325 mg qd, aspirin 325 mg tid, aspirin 325 mg tid  dipyridamole 75 mg tid, sulfinpyrazone 267 mg tid) versus placebo. All aspirin groups have been
combined, and the results for the sulfinpyrazone treatment arm were not included. †In this study, the breakdown of patients in each treatment group was not reported and cannot be inferred. ‡Follow-up time occurred at a median of
12 months. §In this study, the breakdown of patients receiving follow-up angiography was not reported, therefore, this percentage includes patients in the sulfinpyrazone treatment arm. Follow-up time was reported as a mean. ¶The
p value was not explicitly stated in these studies but was reported as nonsignificant. #In these studies, dipyridamole was administered with aspirin. **In these studies, the denominator of both treatment groups do not add up to the total
number with follow-up angiography because there were multiple treatment arms, and only aspirin vs. placebo are reported here. Other treatment arms included aspirin and dipyridamole or warfarin.
bid  two times daily; CABG  coronary artery bypass grafting; MI  myocardial infarction; qd  daily; tid  three times daily.
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RCTs of Post-CABG Medical Therapy January 18, 2005:177–84anged from 325 to 1,200 mg daily. Two of the eight trials
hat examined the effect of aspirin on graft occlusion found
spirin to be beneficial when administered within one day
fter CABG (27,30). In contrast, six of the eight trials
ound graft occlusion to be similar between patients receiv-
ng aspirin when compared with patients receiving placebo
26,28,29,31–33). Four of the latter initiated aspirin be-
ween 2 and 5 days after CABG (29,31–33), one initiated
spirin before CABG (26), and one initiated aspirin at 12
onths after CABG (28). Follow-up times varied between
ne and three years.
Two of the eight trials also studied the effect of aspirin on
ardiovascular events (Table 1). Neither of these studies
ound a significant improvement in the incidence of angina,
I, or death among patients treated with aspirin (26,28). In
he first of the Goldman et al. (26) studies, aspirin was
dministered before CABG, and patients were followed for
2 months. In the second Goldman et al. (28) study, aspirin
as administered at one year after CABG, and patients
ere followed for two years.
Several of the trials had study methodologies that differed
reatly from each other. All the trials reported both number
f bypass grafts and number of patients as their units of
nalysis. However, the efficacy of aspirin sometimes differed
epending on which unit of analysis was used (26,33). In
he first of the Goldman et al. (26) studies, aspirin was
ound to be beneficial on graft occlusion when the number
f bypass grafts was reported as the unit of analysis instead
f the number of patients (26). At one year, rates of graft
cclusion were reduced from 22.6% to 15.8% (p  0.029)
hen various aspirin treatment arms were combined and
ompared with placebo. Similarly, Brown et al. (33) also
ound reduced graft occlusion among patients treated with
spirin versus patients receiving placebo when grafts were
nalyzed as the unit of analysis (odds ratio  0.47,
 0.04).
Treatment arms also varied between studies. For exam-
le, six of the eight trials either had more than two
reatment arms (26,31–33) or combined aspirin with dipy-
idamole or warfarin (26,27,29). As we were only interested
n comparisons of aspirin with placebo, other treatment
rms were not included in our analysis unless aspirin had
een combined with these medications, and separate results
ere not available (26,27,29). Goldman et al. (26) found
imilar rates of graft occlusion in all three different treat-
ent arms (325 mg daily, 325 mg three times daily, and 325
g of aspirin with 75 mg of dipyridamole three times daily)
nd, hence, combined the results of all three groups into
ne. In another study, Goldman et al. (28) randomized
atients at one year after CABG to continued treatment
ith aspirin or placebo for an additional two years.
Several of these studies had a significant proportion of
atients excluded from the final analyses due to a smaller
roportion receiving angiography at follow-up (Table 1).
he percent of patients with follow-up angiographyanged from 50% to 92%. Reasons cited by authors were tatient refusal, loss to follow-up, death, intolerance or
iscontinuation of medications, occlusion of grafts early
n the study, and medical complications such as psychi-
tric problems. All authors reported there to be no
aseline differences between patients undergoing and not
ndergoing follow-up angiography. Thus, this suggested
hat that patients excluded from final analyses did not
epresent a potential source of bias in the results of these
tudies. However, it is difficult to infer the generalizabil-
ty of these results to the larger population of CABG
atients without the use of intention-to-treat analyses. It
s also possible that the exclusion of patients decreased
he power to demonstrate a treatment effect.
In summary, despite the relatively small patient popula-
ions included in these studies and the lack of complete
ngiographic follow-up, current evidence suggests that as-
irin may be beneficial in reducing graft occlusion at 12
onths after CABG when administered within 1 day after
ABG. Evidence is lacking, however, to support the benefit
f aspirin in reducing the incidence of cardiovascular events
t1 year after CABG. Importantly, aspirin is inexpensive,
s associated with few side effects, and is known to be
eneficial for patients with CAD (24). Therefore, aspirin
hould be started immediately after CABG and be contin-
ed indefinitely unless contraindications exist.
NTILIPID AGENTS
hree RCTs involving over 1,900 patients examined the
ffect of antilipid agents on graft occlusion and the risk of
ardiovascular events (as secondary end points) after
ABG: the Post-CABG trial, the Lopid Coronary An-
iography Trial (LOCAT), and the Cholesterol Lowering
therosclerotic Study (CLAS) (34–39) (Table 2). All
hree RCTs found a significant reduction in the progres-
ion of atherosclerosis in bypass grafts. The LOCAT and
LAS trials also reported a significant reduction in the
rogression of native artery disease (36,37). The Post-
ABG and CLAS trials reported long-term follow-up
esults (35,38,39). Antilipid agents were found to only
rovide benefit at decreasing the risk of cardiovascular
vents at 7 years after CABG, as demonstrated in the
LAS trial (39). The trials differed in terms of study
opulation, time of treatment initiation, and type and dose
f antilipid agent used.
The Post-CABG trial randomized 1,351 patients with
rior CABG between 1 and 11 years before randomization
o aggressive versus moderate lipid-lowering treatment with
ovastatin for an average of 4.3 years (Table 2) (34).
ggressive treatment was 40 mg/day, and moderate treat-
ent was 2.5 mg/day. Doses were doubled if target low-
ensity lipoprotein cholesterol levels of 85 mg/dl in the
ggressive treatment group and 140 mg/dl in the moderate
reatment group were not reached with the initial doses. In
ddition, 8 g/day of cholestyramine was added to the
reatment regimen if a patient’s low-density lipoprotein
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January 18, 2005:177–84 RCTs of Post-CABG Medical Therapyevel remained above 95 mg/dl and 160 mg/dl in the
ggressive and moderate treatment groups, respectively,
fter two consecutive visits. Of the 1,351 patients random-
zed in this study, 1,192 or 88% had follow-up angiography.
significantly lower number of patients treated with
ggressive antilipid therapy were found to have progression
f graft atherosclerosis, new graft lesions, and new graft
cclusions at four years. A total of 27% of patients treated
ith aggressive lipid-lowering treatment were found to have
0.6 mm decrease in lumen diameter when compared
ith 39% of patients who received less aggressive treatment
p  0.0001). The composite end point of need for
evascularization, MI, stroke, and cardiac death was signif-
cantly lower among patients treated aggressively at 7.5-year
ollow-up but not at 4 years’ follow-up (35).
The LOCAT study randomized 395 men with low
igh-density lipoprotein at a mean of 22 to 23 months after
ABG to 1,200 mg daily of gemfibrozil versus placebo for
mean of 2.7 years (Table 2) (36). Patients with diabetes
nd low LVEF, two important subgroups of CABG pa-
ients, were excluded from the trial. Of the 395 patients
andomized in this study, 372 (94%) completed follow-up
ngiography. Antilipid treatment was found to significantly
educe the number of new lesions in saphenous vein grafts
2.4% in antilipid group vs. 14.3% in placebo group, p 
.001). The primary end point of change in mean diameter
f native arteries was also found to be significantly lower
mong patients treated with antilipid agents (0.01  0.10
m in antilipid group vs. 0.04 0.11 mm in placebo group,
 0.009). The composite end point of repeat revascular-
zation, MI, or death was not significantly different between
reatment groups.
The CLAS trial randomized 188 nonsmoking men who
nderwent CABG at least three months before enrollment
o 30 g of colestipol and 3 to 12 g of niacin daily versus
able 2. Randomized Controlled Trials of Antilipid Agents in P
Author, Year (Ref.) n Medication and Dose
Treatment
Onset
(No. Month
Post-Op)
ost-CABG, 1997 (34) 1,351 Lovastatin‡ 40 mg qd 12–132
Follow-up, 2000 (35) 1,351
rick et al. (LOCAT),
1997 (36)
395 Gemfibrozil 1,200 mg qd 22–23 13
lankenhorn et al.
(CLAS), 1987 (37)
188 Colestipol 30 g qd/
niacin 3–12 g qd
3
Follow-up, 1990 (38) 103
Follow-up, 1996 (39) 162
The clinical end points reported here were not the primary end points of these studie
s percentages rather than absolute numbers. The numbers reported here have been d
he control group received treatment of 2.5 mg per day of lovastatin versus 40 mg per
dded in certain cases (see text). §Composite end point: death, MI, stroke, CABG, or
eath, MI, CABG, or PCI. #The p value was not explicitly stated in these studies but
n number of patients randomized and included in the analyses for clinical end poi
s in Table 1.lacebo (Table 2) (37). Of the 188 patients randomized in Chis study, 162 (86%) completed follow-up angiography.
fter treatment with these antilipid agents for two years, the
nvestigators found that the number of subjects with new
esions in both native vessels and grafts was significantly
ower among patients treated with antilipid agents than
hose with placebo. A total of 10% of patients treated with
ntilipid agents were found to have new lesions within the
ative vessels compared with 22% of patients treated with
lacebo (p  0.03). Likewise, 18% of treated patients had
ew lesions in bypass grafts compared with 30% of patients
reated with placebo (p  0.04). Cardiac death, MI, and
ngina were not significantly different between treatment
roups at two or four years after CABG (37,38). However,
y seven years after CABG, the composite end point of
epeat revascularization, MI, or cardiac death was signifi-
antly lower among patients treated with antilipid agents
40% vs. 61%, respectively, p  0.02) (39).
In summary, long-term treatment with antilipid agents
n post-CABG patients prevents progression of both
ative coronary artery and graft atherosclerosis as well as
ubsequent cardiovascular events. Although the primary
nd point of these studies was the progression of athero-
clerosis, the use of antilipid agents was found to decrease
he progression of atherosclerosis as early as two years
fter CABG. As past research has also demonstrated a
enefit of antilipid agents in reducing the progression of
therosclerosis of native arteries among CAD patients
ithout a history of CABG, the routine use of antilipid
gents in post-CABG patients appears to be well justi-
ed. As none of these studies started treatment onset at
he time of surgery and only one of the three trials
xamined a statin drug, more research is needed to clarify
oth the time that treatment should be initiated and the
ypes of antilipid agents that might prove beneficial after
ABG Patients
llow-Up
(yrs) End Points*
Antilipid
Agent†
(%)
Control†
(%)
p
Value
4.3 Composite end point§ 85/676 (13) 103/675 (15) 0.12
7.5 Composite end point§ 207/676 (31) 271/675 (40) 0.001
2.7 Composite end point¶ 7/197 (4) 7/198 (4) 0.05#
2 Cardiac death 0/94 (0) 1/94 (1) 0.05#
MI 1/94 (1) 4/94 (4) 0.05#
4 Cardiac death 0/56 (0) 0/47 (0) 0.05#
MI 3/56 (5) 4/47 (9) 0.05#
7 Composite end point** 32/80 (40) 50/82 (61) 0.04
se see text for more details). †For most studies, the numbers of events were reported
from the percentages given and the initial number of patients cited. ‡In this study,
the treatment group with doses doubled in order to reach target levels and colestipol
taneous coronary intervention (PCI). Mean follow-up time. ¶Composite end point:
ported as nonsignificant. **Composite end point: cardiac death, MI, CABG, or PCI.
ease see text for numbers of patients with follow-up angiography); other abbreviationsost-C
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RCTs of Post-CABG Medical Therapy January 18, 2005:177–84ETA-BLOCKERS
nly one RCT examined the effect of beta-blockers after
ABG (Table 3). Sjoland et al. (40) conducted a double-
lind placebo-controlled RCT of 967 patients undergoing
ABG (Table 3). Patients were randomized 4 to 21 days
fter CABG to 50 mg of metoprolol twice a day for two
eeks and 100 mg of metoprolol twice a day thereafter
ersus placebo for two years. There was no difference
etween the two arms of the trial with respect to improve-
ent in exercise capacity among the 618 patients who
eceived an exercise test at follow-up. However, patients
reated with placebo were found to have a higher (worse)
hest pain score when compared with patients treated with
etoprolol (Table 3). In another analysis of the total
umber of patients randomized, none of the end points of
epeat revascularization, unstable angina, nonfatal MI, or
eath were found to be significantly different between the
wo groups at two-year follow-up (41).
In summary, although the use of beta-blockers is indi-
ated among CAD patients with a history of MI and CHF,
nly one RCT has examined the use of beta-blockers in a
eneral post-CABG population. There is, therefore, little
vidence to suggest that beta-blockers should be used
outinely after CABG.
CBs AND NITRATES
nly one RCT examined the effect of CCBs after CABG
Table 3) (42), while no RCTs examined the effect of
itrates. Gaudino et al. (42) evaluated the benefits of CCBs
eyond the first year after CABG on radial artery graft
atency. A total of 120 patients with normal perfusion of
he radial artery were randomized after one year of treat-
ent with 120 mg daily of oral diltiazem to either continued
r suspended treatment. There were no significant differ-
nces at four-year follow-up between the CCB group and
he group whose treatment was discontinued with respect to
ecurrence of angina (10% vs. 12%, respectively, p  0.85),
esidual ischemia (by scintigraphy; 17% vs. 18%, p  0.82),
nd cardiac death (2% vs. 0%, p  0.96).
In summary, there is little evidence to support the routine
se of CCBs or nitrates after CABG. Although short-term
se of CCBs may be useful in patients with radial artery
rafts, long-term RCT data for CCBs is limited and is
bsent for the use of nitrates.
CE INHIBITORS
nly one RCT involving 149 patients specifically evaluated
he benefit of ACE inhibitors after CABG: the Quinapril
n Clinical Outcome After Coronary Artery Bypass Graft-
ng (QUO VADIS) study (Table 3) (43). The primary
bjective of the QUO VADIS study was to evaluate the
fficacy of quinapril (40 mg daily) on the change in total
xercise endurance at one year. Patients underwent exercise
esting both before CABG and at one year after CABG, as Ta
b
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January 18, 2005:177–84 RCTs of Post-CABG Medical Therapyell as Holter monitoring for 48 h at one year. Quinapril
as started one month before CABG and was continued for
ne year. The treatment had no effect on the primary end
oint of change in total exercise endurance or the incidence
f ischemia on Holter. However, 3.5% of patients receiving
uinapril experienced ischemic events such as angina, death,
I, repeat revascularization, stroke, or transient ischemic
ttacks versus 15% of patients receiving placebo (p  0.02).
In summary, only one RCT examined the use of ACE
nhibitors after CABG. Although evidence from this RCT
uggests a beneficial effect of treatment on clinical events at
ne year, more trials with larger numbers of patients and
onger follow-up periods are needed before the routine use
f ACE inhibitors after CABG can be recommended.
tudy limitations. Several potential limitations of our re-
iew should be noted. First, as we were interested in the
ffect of aspirin after CABG, we excluded studies that
xamined the efficacy of aspirin compared with other
nticoagulants or other antiplatelet agents. Therefore, it is
ossible that other agents such as clopidogrel might provide
n added benefit after CABG. Second, most studies that
xamined the efficacy of aspirin were conducted in the 1980s
nd only involved saphenous vein grafts. These studies
rovided little data on arterial grafts. Third, several meth-
dological issues were evident in our review of the literature.
or example, the time that treatment was initiated varied
ubstantially between patients enrolled in the various RCTs,
aking it difficult to draw conclusions as to when treatment
ith these agents should be started. Agents used, dosages,
nd study populations also differed between studies. In some
CTs, large numbers of patients were withdrawn from
lind treatment because patients in the control group were
eceiving open-label non-placebo. Many patients also did
ot complete follow-up angiography. Thus, analyses re-
orted in published reports sometimes presented results for
much smaller group of patients compared with the initial
tudy population. Finally, most patients have a good prognosis
or the first several years after CABG. Therefore, studies with
mall numbers of patients have low power to detect differences
n clinical events early after CABG. The fact that most of the
CTs available for review had small numbers of patients and
hort follow-up times is a major limitation that restricts our
bility to make recommendations.
onclusions. Cardiac medical therapy may play a pivotal
ole in the prevention of angina, MI, repeat revasculariza-
ion, and death in the post-CABG patient. However, in our
eview of the literature, very few RCTs were found that
pecifically examined the efficacy of cardiac medical therapy
fter CABG. The use of aspirin and antilipid agents seems
arranted from the literature. It remains uncertain, how-
ver, how long treatment with either of these medications
hould be continued after CABG, what are the appropriate
oses, which antilipid agents should be used, and when
reatment with antilipid agents should be initiated. More
rials are needed to support the routine use of ACE
nhibitors after CABG, and little evidence is available to
1upport the use of beta-blockers, CCBs, and nitrates after
ABG. The results of this review point to an urgent need
or additional studies investigating cardiac medical therapy
n the post-CABG patient.
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